CO2024012877A2 - Conjugados de fármaco-anticuerpo dirigidos al receptor de folato alfa y métodos de uso - Google Patents

Conjugados de fármaco-anticuerpo dirigidos al receptor de folato alfa y métodos de uso

Info

Publication number
CO2024012877A2
CO2024012877A2 CONC2024/0012877A CO2024012877A CO2024012877A2 CO 2024012877 A2 CO2024012877 A2 CO 2024012877A2 CO 2024012877 A CO2024012877 A CO 2024012877A CO 2024012877 A2 CO2024012877 A2 CO 2024012877A2
Authority
CO
Colombia
Prior art keywords
antibody
drug conjugates
receptor alpha
folate receptor
methods
Prior art date
Application number
CONC2024/0012877A
Other languages
English (en)
Spanish (es)
Inventor
Rupert H Davies
James R Rich
Stuart Daniel Barnscher
Mark Edmund Petersen
Raffaele Colombo
Michael G Brant
Manuel Michel Auguste Lasalle
Dunja Urosev
Sukhbir Singh Kang
Peter Wing Yiu Chan
Samir Das
Rojas Andrea Hernandez
Robert William Gene
Ada G H Young
Samuel Oliver Lawn
Danny Chui
Duncan Browman
Brandon Clavette
Original Assignee
Zymeworks Bc Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zymeworks Bc Inc filed Critical Zymeworks Bc Inc
Publication of CO2024012877A2 publication Critical patent/CO2024012877A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68037—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a camptothecin [CPT] or derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CONC2024/0012877A 2022-03-25 2024-09-24 Conjugados de fármaco-anticuerpo dirigidos al receptor de folato alfa y métodos de uso CO2024012877A2 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202263324003P 2022-03-25 2022-03-25
US202263417250P 2022-10-18 2022-10-18
US202363450607P 2023-03-07 2023-03-07
PCT/CA2023/050406 WO2023178452A1 (en) 2022-03-25 2023-03-24 Antibody-drug conjugates targeting folate receptor alpha and methods of use

Publications (1)

Publication Number Publication Date
CO2024012877A2 true CO2024012877A2 (es) 2024-10-10

Family

ID=88099491

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2024/0012877A CO2024012877A2 (es) 2022-03-25 2024-09-24 Conjugados de fármaco-anticuerpo dirigidos al receptor de folato alfa y métodos de uso

Country Status (11)

Country Link
US (2) US12433952B2 (https=)
EP (1) EP4499698A1 (https=)
JP (1) JP2025510791A (https=)
KR (1) KR20240162575A (https=)
AU (1) AU2023239448A1 (https=)
CA (1) CA3245602A1 (https=)
CL (1) CL2024002860A1 (https=)
CO (1) CO2024012877A2 (https=)
IL (1) IL315393A (https=)
MX (1) MX2024011775A (https=)
WO (1) WO2023178452A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4623936A1 (en) * 2022-11-22 2025-10-01 Keymed Biosciences (Chengdu) Co., Ltd. Fused ring compound, conjugate thereof and use thereof
AU2024253122A1 (en) * 2023-04-07 2025-10-23 Innovent Biologics (Suzhou) Co., Ltd. Antibody-drug conjugates of camptothecin derivatives and uses thereof
WO2024255740A1 (zh) * 2023-06-13 2024-12-19 成都倍特药业股份有限公司 用于治疗或预防癌症的喜树碱衍生物及其抗体药物偶联物
TW202530268A (zh) * 2023-10-19 2025-08-01 加拿大商酵活英屬哥倫比亞有限公司 抗ｎａｐｉ２ｂ抗體－藥物結合物及使用方法
WO2025106278A1 (en) 2023-11-17 2025-05-22 Mersana Therapeutics, Inc. Treatment of cancer using b7-h4-targeted antibody-drug conjugates
WO2025235686A1 (en) * 2024-05-07 2025-11-13 Aarvik Therapeutics, Inc. Fluorocamptothecin compounds, conjugates, and methods thereof
WO2026057740A1 (en) * 2024-09-12 2026-03-19 Astrazeneca Ab Treatment of cancer with therapeutic binding molecules

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9402934D0 (en) * 1994-02-16 1994-04-06 Erba Carlo Spa Camptothecin derivatives and process for their preparation
JP2002255821A (ja) 2001-03-06 2002-09-11 Yakult Honsha Co Ltd 抗癌剤耐性癌に対する治療剤
US7498298B2 (en) 2003-11-06 2009-03-03 Seattle Genetics, Inc. Monomethylvaline compounds capable of conjugation to ligands
PL2635607T3 (pl) 2010-11-05 2020-05-18 Zymeworks Inc. Projekt stabilnego przeciwciała heterodimerowego z mutacjami w domenie FC
CA2854233C (en) 2011-11-04 2020-05-12 Zymeworks Inc. Stable heterodimeric antibody design with mutations in the fc domain
AU2018237683A1 (en) * 2017-03-24 2019-10-31 Seagen Inc. Process for the preparation of glucuronide drug-linkers and intermediates thereof
CA3094313A1 (en) 2018-04-06 2019-10-10 Seattle Genetics, Inc. Camptothecin peptide conjugates
TWI851577B (zh) 2018-06-07 2024-08-11 美商思進公司 喜樹鹼結合物
HUE060364T2 (hu) 2019-03-29 2023-02-28 Medimmune Ltd Vegyületek és konjugátumaik
JP7561141B2 (ja) 2019-04-26 2024-10-03 イミュノジェン・インコーポレーテッド カンプトテシン誘導体
CN110128501A (zh) * 2019-05-21 2019-08-16 北京海美源医药科技有限公司 一种靶向fap酶的喜树碱类化合物及其制备方法和应用
MX2021015887A (es) * 2019-06-24 2022-03-22 Hangzhou Dac Biotech Co Ltd Un conjugado de un agente citotóxico y una molécula de unión a células con enlazadores ramificados.
CN115666642A (zh) * 2020-05-11 2023-01-31 上毅生物科技股份有限公司 含有α-烯醇酶抗体的药物缀合物和其用途
IL299001A (en) 2020-06-19 2023-02-01 Hangzhou Dac Biotech Co Ltd Pairings of a cell-binding molecule with camptocin analogs
CN114569735A (zh) * 2020-12-01 2022-06-03 泰州复旦张江药业有限公司 一种连接基-药物偶联物、制备方法及应用
MX2023008895A (es) 2021-02-09 2023-08-09 Medilink Therapeutics Suzhou Co Ltd Conjugado de sustancia bioactiva, metodo de preparacion y uso del mismo.
IL308734A (en) * 2021-05-27 2024-01-01 Zymeworks Bc Inc Camptothecin analogues, conjugates and methods of use
CN117980327A (zh) 2021-11-03 2024-05-03 杭州多禧生物科技有限公司 抗体的特异性偶联
KR20240162569A (ko) 2022-03-25 2024-11-15 자임워크스 비씨 인코포레이티드 항-엽산 수용체 알파 항체 및 사용 방법

Also Published As

Publication number Publication date
JP2025510791A (ja) 2025-04-15
WO2023178452A1 (en) 2023-09-28
KR20240162575A (ko) 2024-11-15
AU2023239448A1 (en) 2024-11-07
US20250339552A1 (en) 2025-11-06
IL315393A (en) 2024-11-01
CL2024002860A1 (es) 2025-02-21
EP4499698A1 (en) 2025-02-05
US20240424125A1 (en) 2024-12-26
US12433952B2 (en) 2025-10-07
MX2024011775A (es) 2024-11-08
CA3245602A1 (en) 2023-09-28

Similar Documents

Publication Publication Date Title
CO2024012877A2 (es) Conjugados de fármaco-anticuerpo dirigidos al receptor de folato alfa y métodos de uso
MX2019005879A (es) Enlazadores que contienen peptido para conjugados anticuerpo-farmaco.
BR112022017064A2 (pt) Derivados da camptotecina e seus conjugados
CO2023004110A2 (es) Anticuerpos anti-fgfr2 y métodos para usarlos
BR112023024433A2 (pt) Análogos, conjugados e métodos de uso de camptotecina
UY27943A1 (es) Composiciones y mctodos para tratar el crncer usando inmunoconjugados de anticuerpo para cd44 citotnxicos y agentes quimioterapcuticos
MX2018010562A (es) Conjugados de anticuerpo y farmaco basados en eribulina y metodos para su uso.
MX2024005702A (es) Derivado de imida fusionado.
MX2022014231A (es) Conjugados de anticuerpo-farmaco que se enfocan a la uparap.
CO2025004806A2 (es) Novedosos anticuerpos anti-napi2b y conjugados-anticuerpo-droga basados en ellos, métodos terapéuticos y usos de los mismos
MX2025003695A (es) Conjugados de anticuerpo y farmaco que se dirigen a napi2b y metodos de uso
CO2018000414A2 (es) Inmunoconjugados de il22
MX2023015471A (es) Conjugados de anticuerpo-farmaco que comprenden anticuerpos humanizados que eligen como blanco la proteina asociada al receptor activador de plasminogeno tipo uroquinasa (uparap).
ECSP20020949A (es) Conjugados de fármaco-anticuerpo (adc) anti-egfr y sus usos
PH12022553333A1 (en) Markers for use in methods for treating cancers with antibody drug conjugates (adc)
CO2025004508A2 (es) Conjugados de anticuerpo-farmaco dirigidos a glipicano-3 y métodos de uso
MX2025005811A (es) Conjugados de anticuerpo ceacam5-fármaco y métodos de uso de los mismos
CL2023000021A1 (es) Fármacos enlazadores y conjugados de anticuerpo-fármaco antifolato.
CO2025002048A2 (es) Anticuerpos anti monometil auristatina y fragmentos de anticuerpos
CL2023003905A1 (es) Conjugados novedosos que comprenden fosfoantígenos y su uso terapéutico
CL2023002992A1 (es) Anticuerpos anti-c-met y conjugados de anticuerpo-fármaco
MX2024001396A (es) Conjugados anticuerpo-fármaco y métodos de uso de estos.
AR134365A1 (es) CONJUGADOS ANTICUERPO-FÁRMACO QUE SE DIRIGEN A EGFR / c-MET Y MÉTODOS DE PREPARACIÓN Y USOS DE ESTOS
AR130809A1 (es) Conjugados de anticuerpo y fármaco que se dirigen a napi2b y métodos de uso
MX2024008269A (es) Enlazador-fármacos de antifolato y conjugados de anticuerpo-fármaco.